Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Jim Greenwood Says BIO Welcomes Biosimilars; Clarity On Non-inferiority Trials For Substitutability Of Biotech Drugs May Come Up Next Year

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - The entry of biosimilars into the U.S. market will be welcomed by the biotech industry, Jim Greenwood, CEO of the Biotechnology Industry Organization, which represents multinational biotech companies, told the recent BioInvest conference in Mumbai

You may also be interested in...



For BIO, All Roads Lead To India; World Class R&D Apt For Deals But Lack Of Data Protection Create Reticence

For BIO, All Roads Lead To India; World Class R&D Apt For Deals But Lack Of Data Protection Create Reticence

BIO President Jim Greenwood Says Indian Biosimilars Welcome In U.S. Market: An Interview With PharmAsia News (Part 2 of 2)

WASHINGTON - BIO President Jim Greenwood recently returned from a trip across India aimed at drumming up interest in the BIO India Partnering Conference in September 2010; he touted India's burgeoning innovative biotech industry and discussed the growing interest of BIO in seeking new or expanded partnerships with Indian firms.

Table

View full table

Related Content

Scrip
Scrip
Tags:
Latest Headlines

Metsera Launches As New Obesity Contender Flush With $290m

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

See All
UsernamePublicRestriction

Register

SC070520

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By